Hendrik Peter Scholl, the Chief Medical Officer at BELITE BIO, INC (NASDAQ: BLTE), completed a significant divestment of company equity on June 18, 2026. The transaction involved the sale of 10,000 American depositary shares, executed indirectly through the entity Bioptima Ltd. The aggregate value of these transactions reached $1,452,435, with the shares being liquidated at prices ranging between $143.90 and $147.11. This activity represents a notable reduction in insider holdings for the executive overseeing the company's medical operations.
The execution of the sale was structured across multiple price points, reflecting a granular approach to the transaction. The breakdown of the sales includes 96 shares sold at a fixed price of $143.90. A larger portion of the transaction involved 3,748 shares sold at a weighted average price of $144.66, with individual executions occurring within a range of $144.07 to $144.995. Additionally, 4,861 shares were sold at a weighted average price of $145.43, with individual sales ranging from $145.00 to $145.94. Further sales included 1,199 shares at a weighted average price of $146.24, with individual prices spanning $146.005 to $146.755. The final segment of the transaction consisted of 96 shares sold at $147.11. Following these divestments, Mr. Scholl, acting through Bioptima Ltd., retains an indirect stake of 15,000 American depositary shares. Each of these shares represents one ordinary share of the issuer, maintaining the direct correlation between the depositary instrument and the underlying equity.
The insider sale takes place while BLTE stock is trading at $146.12. This current price level marks a 27% decline from the stock's 52-week high of $200. Despite this recent contraction, the equity has demonstrated significant momentum, delivering a 142% return over the past year. Market analysis indicates that the stock remains undervalued relative to its calculated Fair Value. Analyst consensus surrounding the equity is categorized as Strong Buy. The company currently reports a market capitalization of $5.75 billion. Financially, the entity remains unprofitable, recording a loss of $2.54 per share over the last twelve months.
Recent corporate developments provide context for the current market positioning. Belite Bio reported an earnings surprise for the first quarter of 2026. The company achieved an earnings per share of -0.34, which exceeded the forecasted loss of -0.64 by 46.88%. Despite this beat on the earnings metric, the company recorded a net loss of $26.9 million, or $0.68 per share, for the same period. The organization is actively engaged in regulatory processes for its pipeline asset, tinlarebant, a treatment for Stargardt disease. A rolling submission to the U.S. FDA for the New Drug Application began in April 2026. Following the completion of this submission, H.C. Wainwright reiterated a Buy rating with a $200 price target. Mizuho maintained an Outperform rating but adjusted its price target downward to $215 from $223, citing valuation considerations. Benchmark also maintained a Buy rating, setting a price target of $217, citing progress in drug development. Belite Bio plans to present detailed results from its DRAGON Phase 3 trial and submit an NDA in the second quarter of 2026. An interim readout from the PHOENIX trial for tinlarebant in Geographic Atrophy is anticipated in the latter half of 2026.